UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
Nantes, June 9th, 2025, 8 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) informs its shareholders and the market of the update on the terms of the Combined General Meeting scheduled for 25 June 2025 (the 'General Meeting').
In preparation of the General Meeting, OSE Immunotherapeutics has formally submitted to the President of the Nantes Commercial Court a request to extend the date of the General Meeting.
The purpose of this approach is to ensure that the General Meeting is held in a regular and transparent manner and that shareholders are properly informed. It is in response to requests made by some of the Company's shareholders, in a context marked by the filing, by a group of shareholders acting in concert, of several resolutions aimed at substantially changing the composition of the Board of Directors.
Furthermore, the communication of these resolutions to the market did not occur in a timely manner nor under conditions ensuring, at this stage, that shareholders are fully and fairly informed or that the General Meeting is properly or regularly held.
In this respect, the resolutions presented by the group of shareholders acting in concert and which have not been approved by the Board of directors are not identified clearly enough on the voting form posted on the Company's website on June 4th, 2025.
The Company indicates that the resolutions of this group of shareholders, on which the Board of Directors recommends voting against, are renumbered A to K (instead of resolutions n°35 to 44). Apart from this renumbering, all the resolutions remain unchanged.
An amended convening notice will be published in the official legal bulletin.
The voting form along with the preparatory documents for the General meeting required by Article R. 22-10-23 of the French Commercial Code, as amended to include this renumbering, are available on the Company's website: https://www.ose-immuno.com/assemblees-generales/.
OSE Immunotherapeutics considers that the current situation as described above and in the press release dated June 4th, 2025 raises significant legal uncertainties, which justify referring to the judge to extend the date of the General Meeting in order to secure the voting process and ensure that shareholders are consulted in an orderly fashion.
OSE Immunotherapeutics affirms its determination to protect the interests of all its shareholders and to defend the transparency and integrity of its governance, in compliance with the legal and regulatory framework.
OSE Immunotherapeutics will communicate in due course on the progress of this procedure.
ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext.
Additional information about OSE Immunotherapeutics assets is available on the Company's website: www.ose-immuno.com. Follow us on LinkedIn.
Contacts
Fiona Olivierfiona.olivier@ose-immuno.comSylvie Détrysylvie.detry@ose-immuno.com
French Media Contact FP2COMFlorence Portejoiefportejoie@fp2com.fr+33 6 07 768 283
U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@rooneypartners.com+1 212 223 0561
Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
Attachment
EN_250509_Update GM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
18 minutes ago
- New York Times
NATO Chief Urges Members to Spend Far More on Military
The chief of NATO on Monday called on the alliance to make a 'quantum leap in our collective defense,' committing to increases in military spending that far outstrip what Britain and most other members have yet pledged. Speaking in London, Mark Rutte, NATO's secretary-general, laid bare the budget pressures that will face Britain and its European neighbors as they confront the aggression of Russia and the retrenchment of the United States. Mr. Rutte, a former prime minister of the Netherlands, is pushing for members to commit to spending 5 percent of their gross domestic product on military and defense-related activities, a target promoted by President Trump, who complains that the alliance has long unfairly burdened the United States. Mr. Rutte hopes to enshrine the new benchmark at a NATO summit meeting in The Hague on June 24 and 25. But he has yet to set a timeline for when members would be required to meet it — and the goal still seems elusive. Britain has pledged to increase military spending to 2.5 percent of gross domestic product by 2027, paid for by diverting funds from overseas aid. Prime Minister Keir Starmer has set a goal of 3 percent within a decade, though he has refused to give a more specific date without knowing where the money will come from. Ramping up to 5 percent, analysts say, would necessitate politically painful trade-offs for Britain, which is already dealing with straitened public finances. Britain currently spends 2.3 percent of its economic output on defense, more than France or Germany but less than the United States, at about 3.4 percent. Want all of The Times? Subscribe.
Forbes
26 minutes ago
- Forbes
Manchester City's New Signings Mark New Era In Pep Guardiola's Tenure
Manchester City chairman Khaldoon al-Mubarak vowed the club would be 'aggressive' in this summer window after ending last season empty-handed. So far, City has lived up to al-Mubarak's words and then some. In nine days since the transfer window opened, City has already completed the signings of AC Milan and Netherlands midfielder Tijjani Reijnders for £46.3m ($62.7m) and Wolverhampton left-back Rayan Aït-Nouri for £31m ($42m). A deal for Olympique Lyon attacking midfielder Rayan Cherki, meanwhile, has been all but finalized. As per The Athletic, Cherki will move to England for £33.7m ($45.6m). City must register their new signings by 7pm BST (2pm EST) on Tuesday to have them available for the Club World Cup, which begins next week. The significance of City's spending spree is two-fold. First and foremost, it comes with a verdict into alleged breaches of the Premier League's financial rules still hanging over the club. In February 2023, City was formally charged with breaking financial fair play rules between 2009 and 2018 and with failing to co-operate with Premier League investigations into their finances. The club's hearing in the case against the Premier League began on September 16 last year and ran until December 6 in front of a three-person independent commission in London. Back in February, Pep Guardiola admitted he expected the verdict 'within a month'. His forecast has proved to be wide of the mark, with the commission yet to return a judgment six months after the hearing ended. By comparison, it took UEFA just two days to find City guilty of financial manipulation in January 2020, a verdict which was subsequently overturned on appeal. With a judgment still pending, City has wasted no time in reshaping its squad after spending $245m on players in the January transfer window. Omar Marmoush joined from Eintrach Frankfurt, while Savinho and Nico Gonzalez arrived from Troyes and Porto for respectively and centre-back Abdukodir Kushanov signed from Lens. The spending spree was not enough to prevent City from finishing without any silverware for the first time since the 2016-17 season, Guardiola's first campaign in the Premier League. City has won the Premier League six times in the past eight seasons, but finished third 13 points behind eventual champions Liverpool last season and never looked like retaining its crown. The Champions League brought an elimination at the hands of Real Madrid in the Round of 16 and there was heartbreak in the FA Cup final for the second consecutive year with defeat to Cyrstal Palace. In that respect, the arrivals of Reijnders, Aït-Nouri and Chekri point to a clear desire to refresh the squad. Despite the $67.8m arrival of Gonzalez from Porto in January, City's midfield lack of physicality and running power was badly exposed both domestically and in Europe. The issue was exacerbated by the absences of reigning Ballon d'Or winner Rodri, who missed almost the entire season with a knee injury, and Mateo Kovacic. Reijnders' arrival should go some way towards addressing the lack of dynamism in City's engine room. The Dutch international was arguably AC Milan's player of the season, with 10 goals and four assists in Serie A. Among midfielders, only Scott McTominay, had more goal involvements with 16. City's new signing, who turns 27 next month, also ranked fifth for through balls and ninth for forward passes in Serie A last season. Milan signed Reijnders from Dutch side AZ Alkmaar in the summer of 2023 for $22.8m, but he netted only four goals in 50 appearances across all competitions – a figure that should have been much higher. When he met him in Saudi Arabia in January for the Italian Super Cup, former Milan manager Stefano Pioli teased him about his frequent shots off target. Twelve months on, Reijnders found the same promising positions but now with newfound composure, leading to a significant increase in his goal tally. His shots on target more than tripled last season (from 0.25 to 0.87 per match), while his conversion rate more than doubled, soaring from 10% to 23%. With Kevin De Bruyne leaving the Etihad Stadium as a free agent after 10 trophy-laden years and Ilkay Gundogan and Bernardo Silva approaching the winter of their careers, Reijnders could become a key figure in City's midfield. Just like the Dutchman, Aït-Nouri's arrival addresses a glaring weakness in Guardiola's squad. According to Opta stats, in the season just ended among defenders only Trent Alexander Arnold had more goal involvements per 90 minutes than Aït-Nouri, with 0.34 to 0.32 respectively. The prototypical modern full-back, who can use his athleticism to burst forward and is comfortable with the ball at his feet, the Algeria international is a versatile player. Aït-Nouri played at left wing-back under Vitor Pereira following the Portuguese's arrival at Wolves in December. Pereira switched between a five-man defense and a 3-4-3 formation, with the 24-year-old operating as an attacking wing-back in both circumstances. The Algeria international played in the same role under Gary O'Neill, Pereira's predecessor, when he was also deployed further forward as a left midfielder. But of the trio of signings, it is arguably Cherki who is the most intriguing. The 21-year-old is coming off a breakout season, with 12 goals and 20 assists in all competitions and made his France debut last week, scoring in the 5-4 defeat against Spain in the Nations League semi-final. Cherki also scored in both legs of the Europa League quarter-final against Manchester United and was named in the Europa League Team of the Season. Data from Opta shows he outperformed City's attacking midfielders - Phil Foden, Jeremy Doku and Savinho - in all but one category last season, shots per 90 minutes. Cherki and Doku both took 2.2 shots per game, while Savinho and Foden took 2.8 and 3.0 respectively. The Frenchman, however, led the quartet in goals per 90 minutes with a 0.4 figure, compared to Foden and Doku's 0.3 and Savinho's 0.1. Cherki's 0.6 assists per game were the high watermark in the category, when compared with Doku's 0.4, Savinho's 0.3 and Foden's 0.2 and he was also significant better in terms of creating opportunities. The Lyon midfielder set up 3.7 chances per 90 minutes, comfortably ahead of Savinho and Foden with 2.3 and Doku with 2.1. A versatile player who can operate either as attacking midfielder or on the wing, Cherki is gifted with superb technique and looks ready to fill the void left by De Bruyne. Former Arsenal striker and current CBS analyst Thierry Henry said he has "never seen a player in history who dribbles as quickly as him". High praise indeed. The Premier League has been warned.
Forbes
an hour ago
- Forbes
Jacob & Co., Lalique And Bugatti Unveil A $240,000 Artisan Table Clock
The Bugatti Calandre Table Clock created by Jacob & Co., Lalique and Bugatti Three well-known luxury brands joined forces to produce a limited-edition table clock that combines their heritage and artisan knowhow. The Bugatti Calandre Table Clock is the combined creation of luxury watchmaker and jeweler, Jacob & Co., high performance automobile manufacturer, Bugatti, and French luxury glassmaker, Lalique. The research and development as well as the design of this piece took three years alone, the three companies said in a joint statement. The Bugatti Calandre is primarily designed by Jacob & Co., with the luxury brand translating a century of iconic design cues from Bugatti into an intricate timepiece. Lalique crafted the crystal case that helps in translating this tribute to past generations of Bugatti's artistry as well as the visionary future of the iconic automotive brand. Jacob & Co. first references the legendary Bugatti Type 41 Royale with two intricately sculpted Dancing Elephants, serving as an artistic tribute to Rembrandt Bugatti, the renowned sculptor and brother of Ettore Bugatti (1881 – 1947), the founder of Bugatti. In this artistic depiction crafted by Lalique, the elephants are leaning toward each other, a style that defined numerous Lalique clock designs. The name of the product, Calandre (meaning grille), is a nod to Bugatti's French roots and translates Bugatti's iconic horseshoe grille found on its vehicles. The Bugatti brand logo is located on the top part of the grille, in the Bugatti deep red 'macaron' color. In the center of the grille below the clock hands is a vertical flying tourbillon, which references Bugatti's newly released Bugatti Tourbillon hyper sports car. Jacob & Co. has excelled at creating tourbillons over the years. In March, Jacob & Co. released Astronomia Revolution Four-Axis Tourbillon 'Fourth Dimension.' The first watch with four tourbillons. The JCAM58 table clock movement has an eight-day power reserve through the manually wound caliber. The time setting and winding are performed using a special key inserted into the clock's caseback. A close look of the Jacob & Co. vertical tourbillon on the Bugatti Calandre Table Clock Adding the final layer of exclusivity, and a tribute to the high jewelry side of Jacob & Co., the Bugatti Calandre is topped by a 30mm red gemstone. Its color is close to the Bugatti 'Macaron' red color. Jacob & Co. used its signature, patented 'Jacob Cut,' with its exclusive 288 facets in a near-perfect round shape. The case, including the two-elephant artwork was crafted by Lalique from French-made molded crystal, turning a timepiece into an objet d'art. The piece was handcrafted in Lalique's historic workshops in the eastern French town of Wingen-sur-Moder. The Bugatti logo in the Bugatti 'Macaron' red color on the Bugatti Calandre Table Clock The process in creating the case follows traditional methods that date back to the 19th century. Molten crystal is poured into an engineered steel mold, where it cools and solidifies into the sculpture. The clarity, purity and inner light of the crystal ensure that every detail is accentuated when light passes through. Once cast, artisans spent months refining every surface to sharpen edges, enhance textures and frost, and polish finishes. The process involves meticulous casting, cooling and hand-finishing by expert artisans. The intricate frosted and polished surfaces enhance the depth and dimension of the sculpted elephants, Lalique said. Lalique in the statement said there is common ground among the three partners. René Lalique (1860 – 1945) originally began his career as a jeweler, just like Jacob Arabo, the founder of Jacob & Co. René Lalique later became celebrated as a glassmaker and designer after inventing several innovative manufacturing processes that are still in use today. He manufactured numerous hood ornaments, and clocks. One of the Lalique clock styles was to have two figurines symmetrically leaning towards each other above the dial, framing it with their gracious lines. The company adds that René Lalique and Ettore Bugatti shared numerous traits. They were born outside Alsace; the easternmost region of France and they elected to set up their workshops in the area. Both entrepreneurs had found a special set of skills in Alsace. In addition, René Lalique and Ettore Bugatti were business partners in the Clos Sainte Odile, an exclusive venue established more than a 100 years ago that eventually became La Fourchette des Ducs, a Michelin two-star restaurant. The clock is packaged in a bespoke tan leather trunk, similar Bugatti's luxury interiors. The Bugatti Calandre Table Clock is available in a limited edition of 99 pieces. It retails for $240,000.
